Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00265616 · ClinicalTrials.gov registry record · Phase 3
Treatment of Refractory Status Epilepticus
A Phase 3 study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- Phase 3
- Development phase
- 23
- Enrollment target
NCT00265616 is a Phase 3 study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 23 participants.
The verdict
NCT00265616, a Phase 3 study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether propofol or barbiturates should be preferred in the treatment of status epilepticus (continuous seizure activity) refractory to 2 standard antiepileptic agents.
Interventions
- DRUG propofol
- DRUG thiopental/pentobarbital
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2006-05 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00265616
The ClinicalTrials.gov registry entry for NCT00265616 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which propofol is the first listed.
NCT00265616 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00265616 about?
NCT00265616 is a clinical study titled "Treatment of Refractory Status Epilepticus". The purpose of this study is to determine whether propofol or barbiturates should be preferred in the treatment of status epilepticus (continuous seizure activity) refractory to 2 standard antiepileptic agents.
What is the current status of trial NCT00265616?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 23 participants. The study started on 2006-05. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00265616?
The interventions under investigation include: propofol (DRUG), thiopental/pentobarbital (DRUG).
Who is sponsoring clinical trial NCT00265616?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.